ARTICLE | Company News
SciClone will channel Medicines Co. drugs in China
December 19, 2014 2:22 AM UTC
The Medicines Co. (NASDAQ:MDCO) granted SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) exclusive rights to promote cardiovascular drugs Cleviprex clevidipine and Angiomax bivalirudin in China.
SciClone, which sells to a network of Chinese hospital cardiac cathlabs, will be responsible for all pre- and post-launch commercialization efforts, excluding Hong Kong and Macau. In addition to royalties, Medicines Co. is eligible to receive up to $50.5 million, including an undisclosed upfront payment, a product support service fee and milestones. ...